AnAdaptiveInterventionTrial of HomeTesting with BehavioralNudges for ImprovingCOVID-19Testingand PreventionamongPeopleAffected by Diabetes
Project Number1U01DK132737-01
Former Number1U01MH129916-01
Contact PI/Project LeaderWEBER, MARY BETH Other PIs
Awardee OrganizationEMORY UNIVERSITY
Description
Abstract Text
ABSTRACT
This multi-institution team (Emory University, Morehouse School of Medicine, Georgia Institute of Technology),
anchored by the Georgia Center for Diabetes Translation Research (P30DK111024) partnership, proposes
to leverage and expand on the on-going, RADx-UP funded Project PEACH (P30DK111024), to design and
evaluate a home-based COVID-19testing program with behavioralnudges delivered via mobile phone
texts to increase uptake of COVID-19prevention activities (testing, vaccination, preventive behaviors) in “AnAdaptiveInterventionTrial of HomeTesting with BehavioralNudges for ImprovingCOVID-19Testingand PreventionamongPeopleAffected by Diabetes.” COVID-19testing remains a cornerstone in
understanding and managing the COVID-19 pandemic. The state of Georgia faces several challenges to
COVID-19 management including low vaccine rates, over-extended community health partners struggling to
manage both COVID-19testingand vaccination, decreasing COVID-19testing numbers, and large populations
at elevated risk, including those with or at risk for diabetes, individuals at lower socioeconomic levels, and
African American/Black and LatinX communities. In Project PEACH2, we propose to leverage the community
partnerships developed and expanded at part of Project PEACH to gather additional information on COVID-19testing, with a particular focus on at-hometesting solutions (Aim 1), using both quantitative (an expansion of
the follow-up surveys already being conducted as part of Project PEACH) and qualitative (in-depth interviews
with 100 community members, key stakeholders, and community partners) methods. This data, along with the
findings of Project PEACH and Georgia CEAL (1OT2HL156812-01/16-312-0217571-66105L), will be used to
develop text message, behavioralnudges to promote continued COVID-19testing, reporting and preventive
behaviors including vaccination targeted to participants’ race/ethnicity, sex, age, vaccination status, and testing
history. We will then evaluate (Aim 2a) the uptake, usage, and views of a hometesting platform (provision a
single homeCOVID-19 test kit for each household family member, collection of test results via an online
reporting system, and targeted behavioralnudges delivered via text messages) in a randomized community-
based, adaptiveinterventiontrial (n=600) targeting individuals affected by diabetes through collaborations with
community partner sites (faith- and community-based organization, the Grady Diabetes Clinic, COVID-19
community testingand vaccine distribution sites). We will also assess (Aim 2b) how the hometesting platform
affects vaccine uptake and hesitancy among study participants and family members. This study will build on
the successful community-academic partnerships created through Project PEACH to further promote COVID-
19 testingamong the most vulnerable communities in Georgia. Lessons learned can be disseminated to other
at-risk communities and can be adapted to promote home-based testing for other conditions.
Public Health Relevance Statement
NARRATIVE
SARS-CoV-2 testing remains an important priority for long-term pandemic control; however shifting needs and
priorities of the U.S. population have led to decreasing testing rates, even in states like Georgia where COVID-
19 vaccine uptake is low. To enable better adherence to long-term COVID-19testingand preventive
behaviors, we propose a study to understand, design, and test in a randomized, adaptiveinterventiontrial of
600 adults affected with diabetes, at-hometesting with or without individually-targeted, text message,
behavioralnudges targeting COVID-19testing uptake and preventive behaviors, including vaccination.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
310
DUNS Number
066469933
UEI
S352L5PJLMP8
Project Start Date
07-January-2022
Project End Date
31-December-2023
Budget Start Date
07-January-2022
Budget End Date
31-December-2022
Project Funding Information for 2022
Total Funding
$1,156,661
Direct Costs
$934,135
Indirect Costs
$222,526
Year
Funding IC
FY Total Cost by IC
2022
NIH Office of the Director
$1,156,661
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1U01DK132737-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U01DK132737-01
Patents
No Patents information available for 1U01DK132737-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U01DK132737-01
Clinical Studies
No Clinical Studies information available for 1U01DK132737-01
News and More
Related News Releases
No news release information available for 1U01DK132737-01
History
No Historical information available for 1U01DK132737-01
Similar Projects
No Similar Projects information available for 1U01DK132737-01